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A B S T R A C T
Learning associations between stimuli and responses is essential to everyday life. Dorsal striatum (DS) has long
been implicated in stimulus-response learning, though recent results challenge this contention. We have proposed
that discrepant findings arise because stimulus-response learning methodology generally confounds learning and
response selection processes. In 19 patients with Parkinson's disease (PD) and 18 age-matched controls, we found
that dopaminergic therapy decreased the efficiency of stimulus-response learning, with corresponding attenuation
of ventral striatum (VS) activation. In contrast, exogenous dopamine improved response selection accuracy related
to enhanced DS BOLD signal. Contrasts between PD patients and controls fully support these within-subject pat-
terns. These double dissociations in terms of behaviour and neural activity related to VS and DS in PD and in
response to dopaminergic therapy, strongly refute the view that DS mediates stimulus-response learning through
feedback. Our findings integrate with a growing literature favouring a role for DS in decision making rather than
learning, and unite two literature that have been evolving independently.
1. Introduction
Learning to associate responses to specific stimuli seamlessly and
without intent is essential for adaptive behaviour and is the basis for how
organisms interact with and thrive in their environments (Thorndike,
1898). Stimulus-response learning can be probed using many different
paradigms. In humans, the most traditional tasks involve associating
abstract images with a manual response such as a key-press or
button-press response in the presence of feedback (Boettiger and
D'Esposito, 2005; Brovelli et al., 2008; Seger et al., 2010; Hiebert et al.,
2014; Vo et al., 2014; Hampshire et al., 2016). The use of abstract images
or images containing attributes that are difficult to verbalize and cate-
gorize based on previous experience facilitates learning through implicit
mechanisms referred to as procedural learning (Ashby, 1998) mediated
in part by the striatum (Ashby, 1998; Toni and Passingham, 1999).
Additionally, the use of abstract images as opposed to recognizable ob-
jects such as fruit or tools creates more difficulty in learning the
stimulus-response associations, allowing more observations before
learning asymptotes, facilitating a greater exploration of learning
processes.
The view that the dorsal striatum (DS)—consisting of the bulk of the
caudate nucleus and putamen—is critical for stimulus-response learning,
is well-entrenched (Thompson, 1963; Yin and Knowlton, 2006; Brovelli
et al., 2011; Chiu et al., 2017). Despite the prevalence of this view,
learning is often preserved in patients (Exner et al., 2002; MacDonald
et al., 2013; Hiebert et al., 2014; Vo et al., 2014) and animals (Atallah
et al., 2007) with DS dysfunction.
Potentially underlying the discrepancies in the stimulus-response
learning literature, response selection decisions and learning are often
intrinsically confounded (McDonald and Hong, 2004; Jessup and
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O'Doherty, 2011). In stimulus-response learning experiments, trials
generally proceed as follows: a) a stimulus is presented and participants
perform a response, and b) feedback regarding response accuracy is
provided. Feedback is the means through which stimulus-response as-
sociations are learned. Accuracy in selecting a learned response provides
the learning measure. Performance depends upon both decision and
learning processes. Failing either to acquire stimulus-response relations
or to correctly select learned responses produces impaired performance.
Further, in fMRI studies, a) deciding upon and enacting a response, and
b) learning from feedback, are typically treated as a single event with all
significantly activated brain regions ascribed a role in learning per se
(Poldrack et al., 1999; Jessup and O'Doherty, 2011). Accordingly, some
brain regions that might underlie response selection could erroneously be
assigned a role in learning. The objective of the current study was to
directly test this confound in patients with PD, using a stimulus-response
learning paradigm previously shown to separate decisions and learning,
producing differential patterns of activity in dorsal and ventral striatum
(Hiebert et al., 2014).
Combining fMRI with behavioural manipulations in patients with PD
tested both off and on dopaminergic therapy, provides a powerful
approach for investigating striatum-mediated cognitive functions. In PD,
the quintessential motor symptoms arise when dopamine-producing
neurons in the substantia nigra pars compacta (SNc) degenerate to seri-
ously restrict dopamine supply to the DS (Kish et al., 1988). In contrast,
dopamine-producing neurons in the adjacent ventral tegmental area
(VTA) are relatively spared in PD, especially in the early disease stages,
resulting in adequate endogenous dopamine to regions such as VS,
composed of the nucleus accumbens and ventral portions of the caudate
and putamen (Kish et al., 1988). Consequently, in unmedicated PD pa-
tients, DS functions and neural activity are depressed, whereas VS op-
erations and activation levels are spared.
Dopaminergic therapy remediates DS dopamine depletion and im-
proves function (Cools, 2006; MacDonald et al., 2011). Unfortunately,
exogenous dopamine distributes non-selectively, increasing dopamine
even to the relatively-replete VS. As a consequence, dopaminergic med-
ications have been shown to attenuate neural activity and worsen func-
tions performed by VTA-innervated brain regions, presumably due to
dopamine overdose (Cools, 2006; Robertson et al., 2018). In this way,
comparing the OFF and ON states, a double dissociation in terms of
behaviour and neural activity is observed comparing DS and VS.
If DS mediates stimulus-response learning, it is predicted that a) DS
activity will correlate with learning measures and with themoment when
stimulus-response association learning occurs (i.e., the Feedback Event,
when outcome information regarding response accuracy is provided) and
b) learning efficiency and DS signal will improve with dopaminergic
therapy in PD. These outcomes are predicted because the DS is signifi-
cantly dopamine depleted and its functions are impaired at baseline in
PD. DS functions and activity improve with dopamine replacement
(MacDonald and Monchi, 2011).
In contrast, if DS mediates stimulus-response decision performance
and VS mediates stimulus-response association learning, as we expect, a)
DS activity will correlate with accuracy of decision performance and with
the moment when response selection occurs (i.e., the Stimulus-Response
Decision Event), and b) accuracy of stimulus-specific decisions and DS
signal will improvewith dopaminergic therapy in PD. Further, we predict
that a) VS activity will correlate with learning measures and with the
Table 1
Demographic, clinical, screening cognitive, and affective measures for PD patients and healthy controls.
Group N Age Edu Duration Ɩ-dopa (mg) DA (n) UPDRS OFF UPDRS ON
PD 19 65.73 (1.80) 15.21 (0.69) 3.95 (0.60) 599.50 (46.37) 9 12.16 (1.32) 15.26 (1.48)
CTRL 18 65.06 (1.70) 15.00 (0.59) → → → → →
Group ANART MOCA BDI-II OFF BDI-II ON BAI OFF BAI ON Apathy OFF Apathy ON
PD 124.80 (1.63) 27.05 (0.52) 8.31 (1.21) 7.94 (1.23) 7.57 (1.42) 6.47 (1.30) 10.05 (1.06) 10.68 (1.13)
CTRL 124.45 (1.51) 27.00 (0.28) 3.53 (0.56) 3.53 (0.70) 2.41 (0.58) 2.05 (0.55) 9.88 (0.79) 10.29 (0.95)
Fig. 1. Abstract images presented in Phase 1 and Phase 2.
Abstract Image Set A and Set B refer to the images presented either on Session 1 or on Session 2. Images were associated with a button pressed by the index, middle, or
ring finger buttons.
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moment of learning during the Feedback Event, and b) efficiency of
learning and VS signal will decrease with dopaminergic therapy in PD.
These predictions are based on the knowledge that DS functions and
activation improve with dopaminergic therapy in PD, whereas functions
and activation of VTA-innervated brain areas are attenuated by exoge-
nous dopamine in PD, which overdoses these relatively dopamine-replete
regions.
2. Materials and methods
2.1. Participants
Twenty-three participants with PD and 19 age- and education-
matched healthy controls participated in this experiment. All partici-
pants with PD were previously diagnosed by a licenced neurologist, had
no co-existing diagnosis of dementia or another neurological or psychi-
atric disease, and met the core assessment for surgical interventional
therapy and the UK Brain Bank criteria for the diagnosis of idiopathic PD
(Hughes et al., 1992). All PD and no control participants were treated
with dopaminergic therapy. Age- and education-matched controls were
within five years of age (average difference was 3.6 years) and five years
of education (average difference was 2.4 years) to the matched PD pa-
tient. Participants with PD were recruited through the movement disor-
ders database at the London Health Sciences Centre. Participants abusing
alcohol, prescription or illicit drugs, or taking cognitive-enhancing
medications including donepezil, galantamine, rivastigmine, mem-
antine, or methylphenidate were excluded from participating. Three
patients with PD were excluded because they obtained a Montreal
Cognitive Assessment (MoCA) score of 24 or less, and a further one PD
patient and one control participant failed to show any evidence of
learning in Phase 1 in either Session 1 or 2 (explained below) and were
therefore excluded from all analyses. Nineteen patients with PD and 18
age- and education-matched healthy controls were therefore included in
the final analyses.
The motor sub-scale of the Unified Parkinson's Disease Rating Scale
(UPDRS) was scored by a licenced neurologist with sub-specialty training
in movement disorders (P.A.M.) to assess the presence and severity of
motor symptoms for all patients both off and on dopaminergic medica-
tion. Control participants were also screened to rule out undiagnosed
neurological illness. Mean group demographic, as well as cognitive and
affective screening scores for all patients and controls in each experi-
mental group were recorded (Table 1). UPDRS motor subscale scores off
and on dopaminergic therapy, daily doses of dopamine replacement
therapy in terms of L-dopa equivalents (LED), and mean duration of PD
was also recorded (Table 1). Calculation of daily LED for each patient was
based on the theoretical equivalence to L-dopa(mg) as follows: L-dopa
dose(mg)  1 þ L-dopa controlled release(mg)  0.75 þ L-
dopa(mg)  0.33 if on entacapone(mg) þ amantadine(mg)  0.5 þ
bromocriptine(mg)  10 þ cabergoline(mg)  50 þ pergolide(mg)  10
0 þ pramipexole(mg)  67 þ rasagiline(mg)  100 þ ropinirole(mg) 
16.67 þ selegiline(mg)  10 (Wullner et al., 2010).
All participants provided informed written consent to the protocol
before beginning the experiment according to the Declaration of Hel-
sinki. This study was approved by the Health Sciences Research Ethics
Board of the University of Western Ontario.
2.2. Experimental design
Participants with PD were randomly divided into two groups and all
participated in two sessions on separate days. Different stimulus-response
pairs were used in Sessions 1 and 2. Both Sessions 1 and 2 were separated
into two phases. Phase 1, the learning phase, constituted the phase
during which stimulus-response associations were learned through
feedback. Phase 2, the performance phase, comprised the phase during
which stimulus-specific responses learned in Phase 1 were performed
without further feedback. Participants with PD randomly assigned to
Group 1 (OFF-ON) performed Session 1 off dopaminergic therapy and
Session 2 on dopaminergic therapy. In contrast, PD patients randomized
to Group 2 (ON-OFF) performed Session 1 in the ON dopaminergic
therapy state and Session 2 in the OFF state. Although control partici-
pants did not take dopaminergic therapy in either session, their data were
analyzed to correspond to the ON-OFF order of the PD patient to whom
Fig. 2. Example of a single trial in Phase 1 and
Phase 2.
A) Participants learned to associate six abstract
images with one of three button-press responses
in Phase 1. The following is an example of a trial:
(i) a cross appeared in the centre of the projection
screen for 500ms; (ii) a blank screen occurred for
500ms; (iii) an abstract image was presented in
the centre of the projection screen until a button-
press response; (iv) a blank screen appeared for a
variable period of time sampled from an expo-
nential distribution (mean: 2500ms; minimum:
525ms; maximum: 7000ms) (v) feedback (i.e.
‘Correct’ or ‘Incorrect’); appeared for 1000ms;
(vi) a blank screen appeared for a variable period
of time sampled from an exponential distribution
(mean: 2500ms; minimum: 525ms; maximum:
7000ms). B) Participants recalled the responses
to the learned images in the absence of feedback
in Phase 2. Trials in Phase 2 were identical to the
Phase 1 except that feedback was omitted.
* The inter-stimulus and inter-trial intervals (ISI
and ITI, respectively) were jittered between the
response and feedback and between the offset of
feedback and the beginning of the subsequent
trial to create two fMRI events within each trial:
a) the Stimulus-Response Decision Event and b)
the Feedback Event for Phase 1. In Phase 2, the
ITIs were jittered between the response and the
subsequent trial, as the Feedback Event was
omitted.
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they were matched. Matching was performed prior to data analysis at the
time of data collection. This controlled for possible order, fatigue, and
practice effects. Participants with PD took their dopamine medication as
prescribed by their treating neurologist no more than 1.5 h before
beginning their ON testing sessions, but abstained from taking all
dopaminergic medication including dopamine precursors such as L-dopa,
aromatic-L-amino-acid decarboxylase inhibitors such as carbidopa, and
catechol-O-methyltransferase (COMT) inhibitors such as entacapone
(Comtan) for a minimum of 12 to a maximum of 18 h, and dopamine
agonists, such as pramipexole (Mirapex), ropinirole (Requip), or pergo-
lide (Permax), as well as amantadine (Symmeterel), rasagiline (Azilect),
and selegiline (Eldepryl or Deprenyl) for 16–20 h before beginning OFF
testing sessions. All patients confirmed that they complied with these
medication instructions. Ten PD patients and eight controls were in the
OFF-ON group, whereas nine PD and ten controls were in the ON-OFF
group.
In Phase 1, the learning phase of each session, participants learned to
associate abstract images with one of three button-press responses. Im-
ages were computer-generated with GroBoto (Braid Art Labs, Colorado
Springs, USA). In each trial, an abstract image appeared in the centre of a
projection screen until the participant responded with a button-press.
Feedback (i.e., ‘Correct’ or ‘Incorrect’) was provided after every
response and in this way, participants learned to associate each of the
abstract images with the appropriate button-press response through trial
and error. Trials were organized into blocks. After each block, partici-
pants were provided with a percentage score, summarizing their learning
performance. Participants completed a maximum of 12 blocks. Once
participants scored greater than 75% on two successive blocks, Phase 1
ended. Our aim was to examine early learning. Further, we wanted to
avoid accuracy reaching ceiling so that we could also investigate, as a
separate measure, decision performance. If after 12 blocks the participant
was not responding at an accuracy level greater than chance (~33%),
his/her data were not included in the analysis for either the OFF or ON
Sessions. Before proceeding to Phase 1, participants received 20 practice
trials with different images from those employed during the main
experimental sessions to become familiar with the procedure. In Phase 2,
the performance phase of each session, stimuli presented in Phase 1 were
shown again. Participants were asked to provide the stimulus-specific
button-press responses that they had learned in Phase 1. No feedback
was provided to preclude new feedback-based learning during this phase
that was aimed to test selection of accurate responses. Again, different
sets of images were used in Session 1 and Session 2.
Fig. 3. Effect of PD and dopaminergic therapy on learning and response se-
lection.
A) Effect of PD and dopaminergic therapy on adjusted-savings score. Adjusted-
savings score served as a measurement of stimulus-specific response selection
accuracy. Adjusted-savings score was measured using the following equation:
percent accuracy in Block 1 of Phase 2  percent accuracy in the last block of the
Phase 1. Adjusted-savings score was significantly higher in PD patients tested
ON compared to OFF medication. B) Effect of PD and dopaminergic therapy on
slope of learning stimulus-response associations. Slope of learning served as a
measurement of learning efficiency. To reiterate, slope was calculated using the
block accuracy scores over the number of blocks in Phase 1 using the slope of the
linear regression function (Microsoft Excel, 2011). Slope of learning was
significantly slower in PD patients tested ON compared to OFF dopaminergic
medication. All values are presented separately for PD patients tested OFF
medication, PD patients tested ON medication, and control participants tested in
the sessions designated as ON and OFF though control did not actually receive
dopaminergic therapy. Error bars represent standard error of the
mean. *p< 0.05.
Table 2
Significant brain activations in contrasts of interest collapsed across Group (PD
and control) and Medication (OFF and ON) reported in MNI space.
Contrast Anatomical Area Cluster
Size
t q* x, y, z
Phase 1: SR Events
SR minus rest Right dorsal
caudate
75 5.76 <0.001 12, 5, 5








285 6.55 <0.001 48, 32,
32
SR minus FB Right dorsal
caudate
** 7.51 <0.001 12, 5, 2
Left occipital
fusiform gyrus





299 4.89 <0.001 36,
31, 41
Phase 2: SR Events
SR minus Rest Right dorsal
caudate













1713 5.05 <0.001 48, 5,
29
Phase 1: FB Events
FB minus rest Left postcentral
gyrus




299 4.89 <0.001 36,
31, 41


















Cluster size is reported in voxels. *Significance values are reported at q < 0.05
FDR corrected at the voxel level. Coordinates are reported in MNI space. Striatal
regions are presented first and highlighted in each contrast. **Cluster size un-
obtainable as peak coordinates are within a larger cluster.
N.B. SR – Stimulus-Response Decision Events; FB – Feedback Events.
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Both Phases 1 and 2 of Sessions 1 and 2 were performed while fMRI
measures were simultaneously recorded. Twelve abstract images were
used in the experiment, six during each session of testing (Fig. 1). There
were 24 trials per block in Phase 1 of each session, with each abstract
image occurring four times in random order per block. Two images were
assigned to each the second, third, and fourth button on the button box
per session and participants pressed these buttons with their index,
middle, and ring fingers, respectively. A button-press response was
required to advance from the feedback phase to the next trial. In this way,
in each trial, motor responses were included in both Stimulus-Response
Decision and Feedback Events (Fig. 2A).
Trials in the Learning Phases proceeded as follows: (i) a cross
appeared in the centre of the projection screen for 500ms; (ii) a blank
screen occurred for 500ms; (iii) an abstract image was presented until a
button-press response was performed (i.e., the Stimulus-Response Deci-
sion Event); (iv) a blank screen appeared for a variable amount of time
sampled from an exponential distribution (mean: 2500ms; minimum:
525ms; maximum: 7000ms) (v) feedback (i.e., “Correct” or “Incorrect”);
appeared for 1000ms followed by a green circle that appeared in the
centre of the projection screen signifying to the participant to press the
first button with his/her thumb to advance to the next trial (i.e., the
Feedback Event); (vi) a blank screen appeared for a variable amount of
time sampled from an exponential distribution (mean: 2500ms; mini-
mum: 525ms; maximum: 7000ms).
A distractor task lasting approximately 15min (data not shown) was
employed between the Phases 1 and 2 in both Sessions 1 and 2. This was to
prevent rehearsal of stimulus-response associations as well as to make
stimulus-response decisions more challenging. In Phase 2 of each session,
participants performed three blocks of 24 trials, in which the same six
images studied during Phase 1 were presented in random order, four times
per block. Participants provided the button-press response that they had
learned for each image during Phase 1. No feedback regarding accuracy
was provided in Phase 2 of each session, precluding further feedback-based
learning. Parameters for each trial in Phase 2 were otherwise identical to
those in Phase 1 with the exception that the Feedback Event was omitted.
Fig. 2A and B presents example trials in Phases 1 and 2.
2.3. Statistical analysis
2.3.1. Behavioural
Executing stimulus-specific response selections in Phase 2 depended
on how well these associations were learned during Phase 1 in each
session. We hypothesized that PD and medication would affect
learning. We therefore implemented measures to better isolate decision
performance. First, we aimed to equate the degree to which stimulus-
response associations were acquired across participants and sessions
by imposing a learning criterion in Phase 1. That is, once participants
reached a learning criterion of 75% correct on two consecutive blocks
or once they completed 12 blocks, Phase 1 ended. Second, we used an
adjusted-savings score to evaluate accuracy of stimulus-specific
response selections during Phase 2. This score was calculated as fol-
lows for each session:
Table 3
Significant brain activations in omnibus contrasts of interest reported in MNI space.
Contrast Anatomical Area Cluster Size F q* x, y, z
Phase 1: SR Events
Main Effect of Group (PD and control) No suprathreshold activations
Main Effect of Medication (ON and OFF) No suprathreshold activations
Group (PD and control) by Medication (ON and OFF) Interaction Right dorsal caudate 55 9.04 0.010 12, 5, 5
Right lingual gyrus 1616 32.92 <0.001 6, 88, 7
Left postcentral gyrus 629 20.06 <0.001 45, 28, 41
Left insular cortex 196 13.48 <0.001 30, 23, 4
Right precuneous cortex 34 12.66 <0.001 9, 64, 47
Right insular cortex 170 12.51 <0.001 30, 23, 1
Right superior temporal gyrus 91 12.10 <0.001 57, 4, 13
Right lateral occipital cortex 448 11.88 <0.001 39, 58, 41
Right middle frontal gyrus 113 10.78 0.002 45, 35, 29
Left paracingulate gyrus 181 10.20 0.003 3, 20, 44
Left cingulate gyrus 148 9.29 0.008 3, 46, 32
Left angular gyrus 77 9.00 0.010 51, 55, 20
Right angular gyrus 152 8.89 0.011 54, 49, 17
Left frontal pole 147 8.29 0.022 3, 59, 17
Phase 1: FB Events
Main Effect of Group (PD and control) No suprathreshold activations
Main Effect of Medication (ON and OFF) No suprathreshold activations
Group (PD and control) by Medication (ON and OFF) Interaction Right nucleus accumbens 115 6.85 0.050 12, 5, 7
Left postcentral gyrus 6385 19.12 <0.001 39, 28, 47
Right superior temporal gyrus 157 9.63 0.003 57, 4, 13
Left inferior frontal gyrus 385 7.29 0.019 48, 14, 20
Right cerebellum 126 7.59 0.025 18, 52, 22
Left middle frontal gyrus 145 6.93 0.047 33, 26, 32
Cluster size is reported in voxels. *Significance values are reported at q< 0.05 FDR corrected at the voxel level. Coordinates are reported in MNI space. Striatal regions
are presented first and highlighted in each contrast.
N.B. SR – Stimulus-Response Decision Events; FB – Feedback Events.
Table 4









PD patients collapsed across Medication session
i) Stimulus-Response Decision Events in
Phase 1
1.768 8.705 0.561 3.124
ii) Stimulus-Response Decision Events in
Phase 2
4.911 2.396 1.222 0.363
iii) Correct minus Incorrect Feedback
Events minus Rest in Phase 1
0.905 0.963 8.666 7.022
Control participants collapsed across Medication session
i) Stimulus-Response Decision Events in
Phase 1
1.505 3.691 0.827 1.003
ii) Stimulus-Response Decision Events in
Phase 2
2.684 6.870 0.625 0.625
iii) Correct minus Incorrect Feedback
Events minus Rest in Phase 1
0.129 0.117 4.843 7.042
Bayes' factors (BF10) are presented for each of the four anatomical ROIs for
contrasts of interest. Bayes' factors less than three indicate that the results
strongly support the null hypothesis, that activation is not greater than zero.
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% accuracy Block 1 of Phase 2
% accuracy of Last Block of Phase 1
By weighting response-selection performance relative to previous
learning performance in Phase 1, we corrected for learning differences
between participants and across sessions. This score permitted evaluation
of stimulus-specific response selection performance independent of
medication effects on stimulus-response learning.
Efficiency of encoding stimulus-response associations across the
Phase 1 of each session was estimated by the rate of change of correct
responses across the session. The slope of change was measured by
summing the scores obtained at the end of each block over the total
number of blocks required to reach the pre-set learning criterion (i.e.,





where b is the slope, and x and y are the sample means of the number of
blocks and block scores, respectively.
For each of our dependent measures, adjusted-savings score and
slope, 2 2 mixed ANOVAs with Group (PD versus control) and
Medication (ON versus OFF) as the between-subject, and within-
subject variables, respectively were carried out. Simple effects will
be investigated in the case of significant interactions. Simple effects
tests will include:
 Within-subject
 PD OFF versus PD ON
 control OFF versus control ON
 Between-subject
 OFF PD versus control
 ON PD versus control
2.3.2. Imaging acquisition
During data collection of this experiment, the MRI scanner at Robarts
Research Institute at the University of Western Ontario was upgraded.
FMRI data were collected either in a 3 T S Magnetom Trio (before up-
grade) or Magnetom Prisma (after upgrade) with Total Imaging Matrix.
Nine PD patients and seven control participants were scanned on the
Magnetom Trio. The scanning parameters for each scanner before and
after the upgrade were identical. We obtained a scout image for posi-
tioning the participant and T1 for anatomical localization. Number of
runs of T2*-weighted functional acquisitions varied depending on the
participant's rate of learning but ranged from a minimum of one to a
maximum of four runs. Each run was of variable length and therefore
consisted of a variable number of blocks of 24 trials. A distractor task
lasting approximately 15min was administered between Phases 1 and 2
in both sessions. All participants performed Phase 2 as the final fMRI run.
All runs lasted on average 8min with onewhole brain image consisting of
43, 2.5 mm-thick slices taken every 2.5s. The field of view was oriented
along the anterior and posterior commissure with a matrix of 88 88
pixels, an isotropic voxel size of 2.5 2.5 2.5mm3. The echo time was
30ms and the flip angle was 90.
Table 5
Significant brain activations in contrasts of interest for patients with PD OFF versus ON dopaminergic medication reported in MNI space.
Contrast Anatomical Area Cluster Size t p* qSVC x, y, z
Phase 1: SR Events
OFF minus ON SR events No suprathreshold activations
ON minus OFF SR events Right dorsal putamen 44 3.30 <0.001 0.022 21, 2, 14
Phase 2: SR Events
OFF minus ON SR events No suprathreshold activations
ON minus OFF SR events Left dorsal caudate 43 3.68 <0.001 0.024 12, 11, 14
Right dorsal caudate 61 3.45 <0.001 0.037 6, 2, 20
Phase 1: FB Events
OFF minus ON FB events Left ventral putamen 14 3.41 <0.001 0.004 21, 5, 1
ON minus OFF FB events No suprathreshold activations
OFF minus ON Correct minus Incorrect FB events Left ventral putamen 178 3.15 0.001 0.035 21, 20, 1
ON minus OFF Correct minus Incorrect FB events No suprathreshold activations
Cluster size is reported in voxels. p values are reported at a significance level of at p 0.001 uncorrected at the voxel level. Small volume correction (SVC) was applied to
striatal activations using the two DS two VS ROIs taken from Hiebert NM, A Vo et al. (2014). SVC data are presented at a threshold of qSVC<0.05 FDR corrected at the
voxel level. Coordinates are reported in MNI space. Striatal regions are presented first and highlighted in each contrast. **Cluster size unobtainable as peak coordinates
are within a larger cluster.
N.B. SR – Stimulus-Response Decision Events; FB – Feedback Events.
Table 6
Significant brain activations in contrasts of interest for healthy controls in the OFF versus ON groups.
Contrast Anatomical Area Cluster Size t p* qSVC x, y, z
Phase 1: SR Events
OFF minus ON SR events No suprathreshold activations
ON minus OFF SR events No suprathreshold activations
Phase 2: SR Events
OFF minus ON SR events No suprathreshold activations
ON minus OFF SR events No suprathreshold activations
Phase 1: FB Events
OFF minus ON FB events No suprathreshold activations
ON minus OFF FB events No suprathreshold activations
OFF minus ON Correct minus Incorrect FB events No suprathreshold activations
ON minus OFF Correct minus Incorrect FB events No suprathreshold activations
Cluster size is reported in voxels. p values are reported at a significance level of p 0.001 uncorrected for multiple comparisons. p values are reported at the voxel level.
Small volume correction (SVC) was applied to striatal activations using the two DS two VS ROIs taken from Hiebert NM, A Vo et al. (2014). SVC data are presented at a
threshold of qSVC < 0.05 FDR corrected at the voxel level. Coordinates are reported in MNI space. Striatal regions are presented first and highlighted in each contrast.
**Cluster size unobtainable as peak coordinates are within a larger cluster.
N.B. SR – Stimulus-Response Decision Events; FB – Feedback Events.
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2.3.3. FMRI data analysis
Statistical Parametric Mapping Version 8 (SPM8; Wellcome Depart-
ment of Imaging Neuroscience, London, United Kingdom) was used in
conjunction with Matrix Laboratory (MATLAB; MathWorks, Inc., Natick,
Massachusetts, United States) to complete fMRI analysis. Images were
slice-time corrected, reoriented for participant motion, spatially
normalized to the standard Montreal Neurological Institute (MNI) tem-
plate, smoothed with an 8mm full-width half-maximum Gaussian kernel,
and high-pass filtered (0.0056Hz). Realignment parameters used to
correct for head movement were extracted and plotted for each partici-
pant and for each scanning run. A peak movement score was calculated
by averaging the largest amplitude movement across each scanning run.
An independent sample t-test was run on peak movement score between
PD and control participants, and a paired t-test was conducted on PD
patients on and off medication to ensure there was no effect of disease or
medication status on head movement.
Individual participant data were modeled using fixed effects analysis
using SPM8. Regressors were formed using onsets and durations of psy-
chological events of interest, particularly Stimulus-Response Decision,
Feedback, and post-feedback Rest Events, with the canonical hemody-
namic response function. The inter-stimulus interval between Stimulus-
Response Decision and Feedback Events was not explicitly modelled to
minimize over fitting the data. If the randomly generated inter-trial in-
terval (ITI) between the Feedback Event and the Stimulus-Response
Decision Event for the next trial was between 525 and 2000ms, the
final 500ms of this interval was modeled to form the Rest Event. If the ITI
was between 2000 and 4000ms, the final 1000ms comprised the Rest
Event for that trial. Finally, for ITIs that were greater than 4000ms, the
final 2000ms were included as the Rest measure. The aims were to a)
separate the Stimulus-Response Decision, Feedback, and Rest Events as
much as possible, and b) create Rest events with variable durations to
match the Stimulus-Response Decision and Feedback Events. Stimulus-
Response Decision Events were defined as the time from the onset of
the abstract image until the participant made a button-press response.
The Feedback Event was defined as the time from the onset of feedback
(“Correct” or “Incorrect”) until and including the button-press response
that participants made when the green circle appeared on the projection
screen, signalling their readiness to proceed to the next trial. This ended
the Feedback Event. In this way, a motor response occurred during the
Stimulus-Response Decision and Feedback Events.
A single General Linear Model (GLM) was created for Phase 1 in each
session to investigate regional BOLD responses for Stimulus-Response
Decision, Feedback, and Rest Events. Number of predictor functions
corresponded to the number of blocks completed by each participant
multiplied by the three event types (i.e., Stimulus-Response Decision,
Feedback, and Rest). A similar GLM was created to for Phase 2 in each
session to investigate regional BOLD responses for Stimulus-Response
Decision and Rest Events, with regressors corresponding to each of the
three blocks completed in each of the sessions, multiplied by the two
event types (i.e., Stimulus-Response Decision and Rest). Contrasts were
made at the individual level for each session comparing Stimulus-
Response Decision, Feedback, and Rest Events for Phase 1, and
Stimulus-Response Decision and Rest Events for Phase 2. Correct and
incorrect trials were examined separately. At the group level, two GLMs
were created, one for Phase 1 and the other for Phase 2. The Phase 1 GLM
consisted of separate regressors for correct and incorrect Stimulus-
Response Decision minus Rest, and Feedback minus Rest Events for
both PD and control participants, off and on medication, yielding 16
regressors. Age and Order were also added as covariates. Similarly, the
Phase 2 model contained 8 regressors, separated into correct and incor-
rect Stimulus-Response Decision minus Rest Events for both PD and
control participants, off and on medication.
First, group-level contrasts examined events collapsed across Group
(PD and control) and Medication (OFF and ON) to confirm that we
replicated the results from Hiebert et al. (2014). The contrasts of interest
for Phases 1 and 2 were as follows: (i) Stimulus-Response Decision Events
minus Rest in Phase 1, (ii) Stimulus-Response Decision minus Feedback
Events in Phase 1, (iii) Stimulus-Response Decision Events minus Rest in
Phase 2, (iv) Feedback Events minus Rest in Phase 1, (v) Feedback Events
minus Stimulus-Response Decision Events in Phase 1, (vi) correct versus
incorrect Feedback Events in Phase 1. Peaks in these contrasts are re-
ported at a significance level of q< 0.05 corrected for multiple com-
parisons using false discovery rate (FDR) at the voxel level, unless
otherwise noted.
We then performed a set of 2 2 mixed ANOVAs with Group (PD
versus control) and Medication (ON versus OFF) as the between-subject,
and within-subject variables, respectively on activity in Stimulus-
Response Decision and Feedback events separately in Phase 1. The
following contrasts were examined: (i) Main Effect Group (PD versus
control) for Stimulus-Response Decision Events, (ii) Main Effect of
Medication (ON versus OFF) for Stimulus-Response Decision Events, (iii)
Group (PD versus control)Medication (ON versus OFF) Interaction for
Stimulus-Response Decision Events, (iv) Main Effect Group (PD versus
control) for Feedback Events, (v) Main Effect of Medication (ON versus
OFF) for Feedback Events, and (vi) Group (PD versus con-
trol)Medication (ON versus OFF) Interaction for Feedback Events.
Significant GroupMedication interactions were investigated to justify
further exploration of simple effects.
Table 7
Significant brain activations in contrasts of interest for patients with PD versus control participants OFF and ON dopaminergic medication reported in MNI space.
Contrast Anatomical Area Cluster Size t p* qSVC x, y, z
Phase 1: SR Events
PD OFF minus control OFF No suprathreshold activations
control OFF minus PD OFF Left dorsal caudate 10 3.21 0.001 0.027 6, 5, 5
PD ON minus control ON No suprathreshold activations
control ON minus PD ON No suprathreshold activations
Phase 2: SR Events
PD OFF minus control OFF No suprathreshold activations
control OFF minus PD OFF No suprathreshold activations
PD ON minus control ON Left dorsal caudate 8 3.75 <0.001 0.020 12, 11, 17
control ON minus PD ON No suprathreshold activations
Phase 1: FB Events
PD OFF minus control OFF No suprathreshold activations
control OFF minus PD OFF Left ventral caudate 29 3.66 <0.001 0.045 18, 23, 1
PD ON minus control ON No suprathreshold activations
control ON minus PD ON No suprathreshold activations
Cluster size is reported in voxels. p values are reported at a significance level of at p 0.001 uncorrected at the voxel level. Small volume correction (SVC) was applied to
striatal activations using the two DS two VS ROIs taken from Hiebert NM, A Hiebert et al. (2014). SVC data are presented at a threshold of qSVC<0.05 FDR corrected at
the voxel level. Coordinates are reported in MNI space. Striatal regions are presented first and highlighted in each contrast.
N.B. SR – Stimulus-Response Decision Events; FB – Feedback Events.
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We next conducted Bayesian analysis, because critical conclusions
regarding DS's role in stimulus-response learning depend on accepting
null effects. Specifically, refuting the entrenched view that DS mediates
stimulus-response learning is accomplished by showing that a) DS
activation does not arise during the Feedback Event when stimulus-
response associations are learned. There is a justified bias against pub-
lishing negative findings, in that with frequentist approaches, the prob-
abilities of Type II (i.e., falsely failing to reject the null hypothesis) and
Fig. 4. Significant activations in contrasts
collapsing across Group (PD and control) and
medication status (OFF and ON).
Activation t-statistic maps are presented at a
threshold of p 0.001 uncorrected for multiple
comparisons, as well as centred on the striatal
activation for visualization purposes. A) BOLD
signal for Stimulus-Response Decision Events
minus Rest across all blocks in Phase 1. The cross-
hairs are centred on the significant activity that
arose in the right dorsal caudate (peak coordinates:
12, 5, 5; t¼ 5.76, q< 0.001). B) BOLD signal for
Stimulus-Response Decision minus Feedback
Events across all blocks in Phase 1. The cross-
hairs are centred on the significant cluster that
arose in the right dorsal caudate (peak coordinates:
12, 5, 2; t¼ 7.51, q< 0.001). C) BOLD signal for
Stimulus-Response Decision minus Rest Events
across all blocks in Phase 2. The cross-hairs are
centred on the significant activity that arose in
the left dorsal caudate (peak coordinates: 15, 1,
14; t¼ 4.76, q¼ 0.015. D) BOLD signal for correct
minus incorrect Feedback Events across all blocks
in the Phase 1. The cross-hairs are centred on the
significant activation that arose in the right nu-
cleus accumbens (peak coordinates: 18, 11, 7;
t¼ 4.87, q¼ 0.007). A significant cluster was also
present in the left nucleus accumbens (peak co-
ordinates: 18, 11, 1; t¼ 4.49, q¼ 0.016).
N.B. SR – Stimulus-Response Decision Events and
FB – Feedback Events in the figure.
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Type I errors (i.e., falsely rejecting the null hypothesis) are asymmetric.
Type I errors are set at a clear maximum, usually less than 0.05, whereas
Type II errors vary across studies in terms of magnitude and determinants
not pre-determined by the experimenter (Dienes, 2014). Bayesian anal-
ysis allows directly contrasting the probability of the null and the alter-
native hypotheses in a symmetrical way, putting these hypotheses on an
equal footing, and directly comparing the relative fit of the two models
(Dienes, 2014). Bayesian analyses were therefore performed to investi-
gate the strength of null effects that arose. Additionally, the strength of
significant effects was investigated by conducting Bayesian analyses on
the strength of DS and VS activity during Stimulus-Response Decision
and Feedback events, respectively. Bayes' factor one-sample t-tests were
conducted separately for PD patients and control participants, using
average beta values extracted from left and right anatomical DS and VS
ROIs during Feedback and Stimulus-Response Decision Events in the
following contrasts: (i) Stimulus-Response Decision Events across Phase 1
collapsed across Medication session (OFF and ON), (ii)
Stimulus-Response Decision Events across Phase 2 collapsed across
Medication session (OFF and ON), and (iii) Correct minus Incorrect
Feedback events across Phase 1 collapsed across Medication session (OFF
and ON).
ROIs were created using the Automated Anatomical Labeling atlas
(Tzourio-Mazoyer et al., 2002), and WFU PickAtlas (Maldjian et al.,
2003) in conjunction with MarsBaR (Brett et al., 2002). The left and right
DS ROI included left and right dorsal caudate nucleus and left and right
dorsal putamen at a level of z> 2mm in MNI space. The left and right VS
ROIs were similarly created and included the left and right ventral
caudate nucleus and putamen at a level of z 2mm in MNI space, as well
as the nucleus accumbens. DS and VS are not distinct anatomical struc-
tures, which creates difficulty when attempting to separate them in an
fMRI context. In a review, Postuma and Dagher (2006) define VS as z 2,
which we employed. Here, DS refers to portions of the caudate nucleus
and putamen at a level of z> 2mm in MNI space. VS was defined as the
nucleus accumbens, caudate, and putamen at a level of z 2mm in MNI
space.
Using the Bayes' factor of three as the cut-off, previously indicated to
be the Bayesian corollary of p< 0.05 in frequentist hypothesis testing
(Dienes, 2014), we tested whether the extracted beta values were indeed
zero. If the Bayes’ factor of the average beta value is less than three, it
strongly supports the null hypothesis, that the activation level is not
greater than zero.
Next, we investigated brain-behaviour correlations to confirm that
behavioural performance was related to DS versus VS activity patterns.
We tested whether BOLD signal in striatal regions correlated with
behavioural indices of response selection decisions and learning respec-
tively. Specifically, we tested whether activity in two DS versus two VS
ROIs taken from Hiebert et al. (2014), correlated with the
adjusted-savings score (i.e., our measure of response-selection decisions),
and with learning slope (i.e., our measure of learning efficiency). Cor-
relations were performed separately for PD and healthy control groups in
the event that learning and response selection performance differed
across groups collapsed across medication session. The two right and left
DS and two right and left VS ROIs from Hiebert et al. (2014) were
employed for the correlation analysis in the present study using the
MarsBar Toolbox in SPM8 (Brett et al., 2002). DS ROIs were centered on
the dorsal head of the caudate nucleus (x¼18, y¼ 24, z¼ 6), and
dorsal putamen (x¼29, y¼ 9, z¼ 6). For VS, x¼10, y¼ 8, z¼4,
and x¼12, y¼ 18, z¼6, centering on the nucleus accumbens and
ventral caudate nucleus respectively were used. Spherical ROIs centred
on the aforementioned coordinates were created with a radius of 6 mm.
All cortical regions were defined using the Harvard-Oxford Cortical Atlas
in the FMRIB Software Library version 5.0 (FSL v5.0; Analysis Group,
FMRIB, Oxford, United Kingdom). All x, y, z coordinates are reported in
MNI space. Beta values in our ROIs were extracted from four contrasts of
interest: (i) Stimulus-Response Decision Events across Phase 2 for pa-
tients with PD across Sessions 1 and 2 (i.e., off and on dopaminergic
medication), (ii) Feedback Events across Phase 1 for patients with PD
across Sessions 1 and 2 (i.e., off and on medication), (iii)
Stimulus-Response Decision Events across Phase 2 for healthy controls
across Sessions 1 and 2, and (iv) Feedback Events across Phase 1 for
healthy controls across Sessions 1 and 2. These average beta values for
each ROI were correlated with behavioural measures of stimulus-specific
response selection (i.e., the adjusted savings scores) and learning (i.e.,
slope values) for each group separately. Outlier analysis was performed
for each significant correlation independently, using the interquartile
Fig. 5. Brain-behaviour correlations between BOLD signal in ROIs and measures
of learning and stimulus-specific response selection.
A) Beta values extracted from the left dorsal caudate ROI in the Stimulus-
Response Decision Events minus Rest contrast correlated positively and signif-
icantly with adjusted-savings in patients with PD on and off medication. B) Beta
values extracted from the right dorsal putamen ROI significantly correlated with
adjusted savings in healthy controls. C) Beta values extracted from the right
anterior VS ROI in the Feedback Events minus Rest contrast, correlated posi-
tively and significantly with slope of learning in patients with PD on and
off medication.
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method. Briefly, data points located 1.5 interquartile range below the
first quartile, and 1.5 interquartile range above the third quartile were
removed, and the correlation was recalculated with the remaining data
points.
Subsequently, events of interest were examined for PD and healthy
controls separately comparing OFF and ON Medication sessions directly.
These within-subject contrasts of interest for Phases 1 and 2 were as
follows: (i) PD OFF versus ON Stimulus-Response Decision Events in
Fig. 6. Significant activations in contrasts exam-
ining only PD patients ON and OFF dopaminergic
medication.
Activation t-statistic maps are presented at a
threshold of p 0.001 uncorrected for multiple
comparisons and centred on the striatal activa-
tion. A) BOLD signal for ON minus OFF Stimulus-
Response Decision Events across all blocks in
Phase 1. The cross-hairs are centred on the sig-
nificant cluster that arose in the right dorsal pu-
tamen (peak coordinates: 21, 2, 14; t¼ 3.30,
p< 0.001, qSVC¼ 0.022). B) BOLD signal for ON
minus OFF Stimulus-Response Decision Events
across all blocks in Phase 2. The cross-hairs are
centred on the significant activity that arose in
the right dorsal caudate (peak coordinates: 12, 11,
14; t¼ 3.68, p< 0.001, qSVC¼ 0.024). Significant
activity also occurred in the left dorsal caudate
(peak coordinates: 6, 2, 20; t¼ 3.45, p< 0.001,
qSVC¼ 0.037). C) BOLD signal for OFF minus ON
Feedback Events across all blocks in the Phase 1.
The cross-hairs are centred on the significant
cluster in the left ventral putamen (peak co-
ordinates: 21, 5, 1; t¼ 3.41, p< 0.001,
qSVC¼ 0.004). D) BOLD signal for OFF minus ON
correct minus incorrect Feedback Events across
all blocks in Phase 1. The cross-hairs are centred
on the cluster of activation in the left ventral
putamen (peak coordinates: 21, 20, 1; t¼ 3.15,
p¼ 0.001, qSVC¼ 0.035).
N.B. SR – Stimulus-Response Decision Events and
FB – Feedback Events in the figure.
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Phase 1, (ii) PD OFF versus ON Stimulus-Response Decision Events in
Phase 2, (iii) PD OFF versus ON medication for Feedback Events in Phase
1, (iv) PD OFF correct minus incorrect Feedback Events versus ON correct
minus incorrect Feedback Events, (v) control OFF versus ON Stimulus-
Response Decision Events in Phase 1, (vi) control OFF versus ON
Stimulus-Response Decision Events in Phase 2, (vii) control OFF versus
ON medication for Feedback Events in Phase 1, and (viii) control OFF
correct minus incorrect Feedback Events versus ON correct minus
incorrect Feedback Events. For OFF-ON contrasts in PD patients and
controls, peaks within the striatum were considered predicted and are
reported at a significance level of p 0.001, uncorrected for multiple
comparisons. To increase confidence in these uncorrected results, small
volume correction (SVC) was applied to striatal activations using the two
DS and two VS ROIs taken from Hiebert et al. (2014). SVC data are
presented at a threshold of q< 0.05 FDR corrected at the voxel level and
appear alongside whole-brain results in Tables 5–7. Peaks outside of the
striatum are reported at a threshold of q< 0.05 FDR corrected at the
voxel level. Striatal regions were again defined using the Harvard-Oxford
Subcortical Atlas in the FMRIB Software Library version 5.0 (FSL v5.0;
Analysis Group, FMRIB, Oxford, United Kingdom).
Next, to clarify our within-subject contrasts that explored the effects
of dopaminergic therapy on DS and VS function in PD patients, we
contrasted Group (PD versus control) in each of the Medication states
separately. The contrasts of interest for Phases 1 and 2 were as follows: (i)
Stimulus-Response Decision Events minus Rest in Phase 1, (ii) Stimulus-
Response Decision minus Feedback Events in Phase 1, (iii) Stimulus-
Response Decision Events minus Rest in Phase 2, (iv) Feedback Events
minus Rest in Phase 1, (v) Feedback Events minus Stimulus-Response
Decision Events in Phase 1, (vi) correct versus incorrect Feedback
Events in Phase 1. For OFF-ON contrasts in PD patients and controls,
peaks within the striatum were considered predicted and are reported
both at a significance level of p 0.001, uncorrected for multiple com-
parisons at the whole-brain level and corrected for multiple comparisons
using SVC (as above). Peaks outside of the striatum are reported at a
threshold of q< 0.05 FDR corrected at the voxel level.
3. Results
3.1. Behavioural data
Demographic, affective, and clinical data are presented in Table 1 and
behavioural data for Phases 1 and 2 are presented in Fig. 3.
3.1.1. Demographic, affective, and clinical data
There were no significant demographic differences between PD and
control participants (Table 1). Participants with PD scored significantly
higher on both Beck Depression Inventory II and Beck Anxiety Inventory
compared to controls regardless of medication status as is expected based
on previous research. No differences were found in terms of depressive or
anxiety symptoms between participants with PD measured off or on their
dopaminergic medication. UPDRS scores were significantly higher in
participants with PD measured off relative to on dopaminergic medica-
tion (t> 6.00, p< 0.0001), signifying greater PD signs when patients
were in the unmedicated state. There were no significant differences in
peak headmovement between PD patients and healthy controls (t¼ 0.08,
p¼ 0.94) or between PD patients on and off medication (t¼ 0.76,
p¼ 0.46).
3.1.2. Response selection decision behavioural measure
Accuracy of selecting previously-learned stimulus-specific responses
was measured using an adjusted-savings score. The score obtained in
Block 1 of Phase 2 was weighted relative to the final accuracy obtained
during the last block of Phase 1 for each session. A 2 2mixed ANOVA of
the adjusted-savings scores was conducted with Group (PD versus con-
trol) as between-subject factor and Medication Session (OFF versus ON)
as the within-subject variable. There were no significant main effects of
Group (F< 1) or Medication (F1,32¼ 1.327, MSE¼ 235.00, p¼ 0.258).
The GroupMedication interaction trended toward significance,
F1,32¼ 4.007, MSE¼ 235.00, p¼ 0.054, and was further investigated
using pairwise comparisons. This revealed a significantly improved
adjusted-savings score for participants with PD tested ON compared to
OFF dopaminergic medication (t¼ 2.24, p¼ 0.038; Fig. 3A) as would be
predicted if DS mediates decisions or response selections. There were no
significant differences between OFF and ON sessions for control partic-
ipants (t¼ 0.70, p¼ 0.494). Recall that control participants did not
actually receive dopaminergic therapy but their data were analyzed to
correspond to the ON-OFF order of the PD patient to whom they were
matched. Additionally, there were no significant differences between PD
and control groups for either the OFF (t¼ 1.26, p¼ 0.104) or ON
(t¼ 0.50, p¼ 0.308) contrast.
3.1.3. Stimulus-response association learning measure
Efficiency of stimulus-response association learning was estimated
using the slope of accuracy change over the total number of blocks
required to reach the learning criterion in Phase 1 (i.e., 75% accuracy on
two consecutive blocks). Slope was calculated using the linear regression
function in Microsoft Excel (2011). A 2 2 mixed ANOVA on the slopes
of learning obtained during Phase 1 was conducted with Group (PD
versus control) as the between-subject factor and Medication Session
(OFF versus ON) as the within-subject variable. There were no main ef-
fects of Group (F< 1) or Medication (F< 1). However, the
GroupMedication interaction was significant, F1,35¼ 4.46,
MSE¼ 0.004, p¼ 0.042. Investigated further using pairwise compari-
sons, we found significantly slower learning ON relative to OFF medica-
tion for PD patients (t¼ 2.17, p¼ 0.044; Fig. 3B) but no medication
difference for control participants (t¼ 0.92, p¼ 0.368), replicating what
we found previously in patients with PD (Hiebert et al., 2014; Vo et al.,
2014) and supporting the dopamine overdose hypothesis. Additionally,
there were no significant slope differences between PD and control
groups for either the OFF (t¼0.17, p¼ 0.568) or ON (t¼ 0.85,
p¼ 0.200) contrast.
3.2. FMRI data
Significant activations in contrasts of interest are presented in
Tables 2–7 and Figs. 4 and 6. Contrasts collapsing across Group and
Medication Session are reported at a significance level of q< 0.05 FDR
corrected at the voxel level. Contrasts examining patients with PD versus
healthy controls, as well as exploring each group separately for OFF-ON
effects are reported at a significance level of p  0.001 for predicted
striatal regions, uncorrected for multiple comparisons and corrected for
multiple comparisons using SVC.
3.2.1. Groups and medication sessions collapsed
3.2.1.1. Stimulus-response decision events. Significant activity in the right
dorsal caudate occurred during the Stimulus-Response Decision relative
to Rest in Phase 1 (peak coordinates: 12, 5, 5; t¼ 5.76, q< 0.001; Fig. 4A).
Significant right dorsal caudate activity also occurred in the Stimulus-
Response Decision minus Feedback contrast in Phase 1 (peak co-
ordinates: 12, 5, 2; t¼ 7.51, q< 0.001; Fig. 4B). When Stimulus-Response
Decision Events were compared to Rest in Phase 2, significant activity in
the left dorsal caudate (peak coordinates: 15, 1, 14; t¼ 4.76, q¼ 0.015;
Fig. 4C) occurred. DS was preferentially recruited during the Stimulus-
Response Decision Event, in both Phases 1 and 2, replicating our previ-
ous findings (Hiebert et al., 2014).
3.2.1.2. Feedback learning events. Correct and incorrect Feedback Events
combined relative to Rest or relative to Stimulus-Response Decision
Events revealed no significant striatal activations. Significant VS but not
DS activity occurred in the left (peak coordinates: 18, 11, 1; t¼ 4.49,
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q¼ 0.016; Fig. 4D), and right nucleus accumbens (peak coordinates: 18,
11, 7; t¼ 4.87, q¼ 0.007; Fig. 4D), in the correct minus incorrect
feedback contrast, however. No significant striatal region was active in
the reverse (i.e., incorrect minus correct) contrast.
3.2.2. Group (PD vs. control) x medication (OFF vs. ON) analysis
2 2 mixed ANOVAs with Group (PD versus control) and Medication
(ON versus OFF) as the between-subject, and within-subject variables,
respectively, were conducted on activity in Stimulus-Response Decision
and Feedback events separately in Phase 1.
3.2.2.1. Phase 1 Stimulus-response decision events. The main effects of
Group and Medication did not reach significance within or outside the
striatum. However, a significant Group (PD and control)Medication
(ON and OFF) interaction effect occurred for Stimulus-Response Decision
Events revealing above-threshold right dorsal caudate activation (peak
coordinates: 12, 5, 5; F¼ 9.04, q¼ 0.010).
3.2.2.2. Phase 1 feedback events. The main effects of Group and Medi-
cation did not reach significance for the Feedback Events. Again, how-
ever, the Group (PD and control)Medication (ON and OFF) interaction
was significant examining feedback events revealing activation in the
right nucleus accumbens (peak coordinates: 12, 5, 7; F¼ 6.85,
q¼ 0.050). These interactions justify exploration of the simple effects
below. Striatal and extra-striatal brain regions that were significantly
activated during these contrasts are presented in Table 3.
3.3. Bayesian analysis
Beta values extracted from the two right and left anatomical DS and
VS ROIs from key contrasts of interest involving Stimulus-Response
Decision and Feedback Events (Table 4). Bayes' factor one-sample t-
tests were conducted on beta values for each of the four ROIs extracted
from each contrast of interest. In this analysis, a Bayes’ factor of less
than three is considered to significantly support the null hypothesis
(Dienes, 2014).
3.3.1. Phase 1 Stimulus-response decision events
Contrasting Stimulus-Response Decision minus Rest events for Phase
1 in PD patients, collapsed across Medication session revealed a Bayes'
factor greater than three in the Right DS in both PD patients and control
participants, separately (Right DS: BF10¼ 8.705; Right DS: BF10¼ 3.691,
respectively). Bayes’ factor for Right VS was also greater than three in PD
patients only (BF10¼ 3.124).
3.3.2. Phase 2 Stimulus-response decision events
Contrasting Stimulus-Response Decision minus Rest events for Phase
2, collapsed across Medication session, revealed Bayes’ factors greater
than three in Left DS for PD patients (BF10¼ 4.911), and Right DS for
control participants (BF10¼ 6.870).
3.3.3. Phase 1 correct minus incorrect feedback events
In the correct minus incorrect Feedback Events, collapsed across
Medication session, PD patient's Bayes' factors for DS ROIs were far below
three, indicating that beta values in these regions were not significantly
above zero (Left DS: BF10¼ 0.905; Right DS BF10¼ 0.963). In contrast,
Bayes' factors for VS ROIs were above three indicating that VS is pref-
erentially activated during these events with beta values significantly
above zero (Left VS: BF10¼ 8.666; Right VS: BF10¼ 7.022). A similar
pattern arose in control participants (Left DS: BF10¼ 0.129; Right DS
BF10¼ 0.117; Left DS: BF10¼ 4.843; Right DS BF10¼ 7.042).
3.4. Brain-behaviour correlations: PD and controls separately
Two right and left VS and two right and left DS ROIs utilized here
were previously employed in Hiebert et al. (2014)—the study in which
the current cognitive paradigm was first explored with fMRI in healthy
young controls. BOLD signal in these ROIs was correlated with our
behavioural measures of stimulus-response decision accuracy and
feedback-based learning efficiency. The adjusted-savings score served as
our measure of decision accuracy, and the slope of change in correctly
associating stimuli and responses was used our measure of
stimulus-response association learning.
3.4.1. Striatum and response-selection decisions
Beta values from each of the ROIs were correlated with adjusted-
saving scores in OFF and ON sessions for PD patients and healthy con-
trols separately. For PD patients, beta values extracted during Stimulus-
Response Decision Events in Phase 2 from the left dorsal caudate ROI
positively correlated with adjusted savings scores (r¼ 0.35, t¼ 2.19,
p¼ 0.035; Fig. 5A). Using the interquartile method, outliers were
removed and the correlation was recalculated. Without the outliers, the
correlation was no longer significant (r¼ 0.32, t¼ 1.88, p¼ 0.071). For
control participants, beta values extracted from the right dorsal putamen
ROI significantly correlated with adjusted savings (r¼ 0.35, t¼ 2.18,
p¼ 0.042; Fig. 5B). The presence of outliers was investigated using the
interquartile method and none were found. Neither of the VS ROIs
correlated with adjusted-savings scores in either the PD or the healthy
control group.
3.4.2. Striatum and learning from feedback
Beta values from each of the VS and DS ROIs were correlated with
slope of learning in the OFF and ON sessions combined for PD patients
and healthy controls separately. A significant positive correlation arose
between slope and beta value in the right ventral caudate ROI (r¼ 0.34,
t¼ 2.17, p¼ 0.037; Fig. 5C) for PD patients only. No outliers were found
in this correlation using the interquartile method. No other ROIs corre-
lated significantly with slope. Of greatest significance given our aim of
directly testing the notion that DS mediates stimulus-response learning, levels of
activation in our DS ROIs did not correlate with the slope of stimulus-response
learning in either the PD or control groups.
3.5. PD patients: OFF vs. ON sessions
Data comparing patients with PD ON and OFF medication are pre-
sented in Table 5 and Fig. 6.
3.5.1. Stimulus-response decision events OFF minus ON
There was no preferential activity in the striatum in this contrast for
Phase 1 or 2 data.
3.5.2. Stimulus-response decision events PD ON minus OFF
Significant right dorsal putamen (peak coordinates: 21, 2, 14; t¼ 3.30,
p< 0.001, qSVC¼ 0.022) activity arose in the ON relative to OFF Session
for Stimulus-Response Decision Events in Phase 1 (Fig. 6A). Significant
left (peak coordinates: 12, 11, 14; t¼ 3.68, p< 0.001, qSVC¼ 0.024) and
right dorsal caudate (peak coordinates: 6, 2, 20; t¼ 3.45, p< 0.001,
qSVC¼ 0.037) activity occurred in the ON relative to OFF Session for the
Stimulus-Response Decision contrast in Phase 2 (Fig. 6B). Overall, these
results reveal a task-specific, dopaminergic therapy-related DS BOLD
signal enhancement for decision enactment.
3.5.3. Feedback learning events OFF minus ON
When Feedback Events were investigated in the OFF minus ON
contrast, significantly greater activity occurred in the left ventral puta-
men (peak coordinates: 21, 5, 1; t¼ 3.41, p< 0.001, qSVC¼ 0.004;
Fig. 6C), suggesting that medication dampened VS activity.
3.5.4. Feedback learning events ON minus OFF
No significant activity occurred in this contrast.
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3.5.5. Feedback learning correct minus incorrect events OFF minus ON
Significantly greater activity occurred in the right ventral putamen,
extending into the nucleus accumbens and ventral caudate (peak co-
ordinates: 18, 11,4; t¼ 3.15, p¼ 0.001, qSVC¼ 0.035) when PD patients
were tested off relative to on dopaminergic therapy. Again, this suggests
that dopaminergic therapy attenuates VS activity, consistent with the
dopamine overdose hypothesis.
3.5.6. Feedback learning correct minus incorrect events ON minus OFF
No significant striatal activity occurred in this contrast.
3.6. Healthy control: ON vs. OFF sessions
There was no preferential activity in the striatum in any contrasts
comparing OFF and ON sessions in healthy controls (Table 6). This is as
expected given that healthy control participants did not actually receive
dopaminergic therapy in any condition and their data were simply
analyzed to correspond to the OFF-ON state of the PD patient to whom
they were matched.
3.7. PD versus controls
Contrasts comparing activity between PD and control groups are
presented in Table 7.
3.7.1. OFF Stimulus-response decision events
Contrasting PD minus control revealed no significant striatal activity
in Phases 1 or 2. However, in the control minus PD contrast, controls
exhibited significantly greater activation in the right dorsal caudate nu-
cleus (peak coordinates: 6, 5, 5; t¼ 3.21, p< 0.001, qSVC¼ 0.027) than PD
patients who were in the OFF state in Phase 1. No significant activity
arose in Phase 2 comparing control and PD participants.
3.7.2. ON Stimulus-response decision events
When PD patients were corrected with exogenous dopaminergic
therapy in the ON Session, no significant striatal activity arose in the PD
minus control or control minus PD contrasts. In Phase 2, in fact, signifi-
cantly greater activation arose in the left (peak coordinates: 12, 11, 17;
t¼ 3.75, p< 0.001, qSVC¼ 0.020) and for PD patients relative to healthy
age-matched controls. Recall that age-matched controls did not actually
receive dopaminergic therapy and rather their data were simply analyzed
to correspond to the dopaminergic state of the PD patient to whom they
were matched. No significant striatal activity occurred in the reverse
contrast (i.e., control minus PD).
3.7.3. OFF feedback events
No significant striatal activity arose for OFF sessions in the PD minus
control contrast. A significant cluster arose in the left ventral caudate
(peak coordinates: 18, 23, 1; t¼ 3.66, p< 0.001, qSVC¼ 0.045) in the
control minus PD contrast.
3.7.4. ON feedback events
Contrasting PD minus control or control minus PD revealed no sig-
nificant striatal activity.
4. Discussion
In both Phases 1 and 2 across Sessions 1 and 2, we found that DS
activity correlated preferentially with Stimulus-Response Decision
Events and not with Feedback Events. It is notable that feedback-based
learning was precluded by the omission of feedback in Phase 2. DS
activation persisted in Phase 2 nonetheless, further casting doubt on DS's
role in feedback-based learning. We also found that beta values in the left
dorsal putamen in healthy controls in Phase 2 correlated with the accu-
racy of stimulus-specific response selections (i.e., adjusted savings score),
intended as our behavioural measure of decision making.Most significant,
given our aim of critically testing DS's role in stimulus-response learning
though, intensity of activation in DS ROIs did not correlate with our behav-
ioural measure of learning efficiency in either the PD or control group. These
results implicate DS in stimulus-specific response decisions entirely
replicating our main finding in Hiebert et al. (2014), in which we used
this paradigm in healthy young controls.
In contrast, in Phase 1 only, VS was preferentially activated during
correct relative to incorrect Feedback Events. The Feedback Event in each
trial is the moment during which learning stimulus-response relations
occurs through deterministic outcome information. Further, we found
that beta values in a VS ROI (i.e., right ventral caudate in the PD group)
correlated significantly with learning slope, our measure of learning ef-
ficiency but not with adjusted-savings score our measure of decision
accuracy. These findings support a role for VS in stimulus-response as-
sociation learning also replicating our results with healthy young con-
trols in Hiebert et al., (2014).
In agreement with our frequentist behavioural and fMRI analyses
presented above, using Bayesian analyses we found that in both PD pa-
tients and healthy controls investigated separately, activation in DS ROIs
correlated significantly with Stimulus-Response Decision Events in both
Phases 1 and 2 of the experiment. In contrast and of critical importance
given the main aim of our study, with Bayesian analysis, we confirmed
that activation in DS ROIs was not significantly associated with stimulus-
response association learning during Feedback events (i.e., the null hy-
pothesis was supported). VS ROI beta values were significant during the
Feedback event using Bayesian analyses concordant with our other in-
vestigations in suggesting that the VS mediates stimulus-response asso-
ciation learning through feedback.
Strongly supporting these distinct cognitive roles for DS and VS, PD
patients evidenced impaired response-selection performance, using the
adjusted-savings score, off medication, which was normalized to control-
level performance by dopaminergic therapy. It should be noted that we
cannot clearly disentangle whether dopaminergic therapy improved
recall of the stimulus-response associations or selection among responses
with weakened associations to stimuli following delay and distraction.
Both are critical components for accurate decision phase performance
and indeed decision making. Conversely, efficiency of learning stimulus-
response associations, assessed by our slope of learning measure, was
equivalent for PD patients and healthy controls, off dopaminergic
medication. However, the slope of learning was worsened by dopami-
nergic medication in our PD group. Recall that in PD, DS is dopamine
depleted and its functions are impaired in the OFF state. DS functions are
remediated by dopaminergic therapy. In contrast, VTA-innervated brain
areas such as VS are relatively dopamine replete and their functions are
normal at baseline. Their functions are actually worsened due to dopa-
mine overdose in the ON state (Cools, 2006). Entirely confirming our
interpretation of the behavioural patterns, DS signal associated with the
Stimulus-Response Decision Event was enhanced by dopaminergic
medications in PD patients using within-subject contrasts. In contrast,
Feedback Event-related VS signal was depressed by exogenous dopamine
therapy (i.e., dopamine overdose effect).
In contrast to our findings in PD, for healthy controls who did not
actually receive dopaminergic therapy but whose data were analyzed to
correspond to the ON-OFF order of the PD patients to whom they were
matched, there were no response-selection accuracy or learning effi-
ciency differences, or differential patterns of fMRI activity comparing the
ON versus OFF sessions, as expected. These findings in controls suggest
that differences observed for PD patients were not the result of order,
practice, or stimulus effects across the OFF and ON sessions.
Bolstering our within-subject patterns in PD, between-group com-
parisons revealed that DS activation in PD patients was reduced relative
to DS activation in healthy age-matched controls in the OFF state during
Stimulus-Response Decision Events. DS activation between PD and
healthy controls was equivalent, however, in the ON Sessions, once PD
patients were medicated with dopaminergic therapy. Further, VS, but not
DS, activation was decreased for PD patients relative to healthy controls
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in the ON Session in the exact region (i.e., left ventral putamen) where
dopaminergic therapy attenuated VS activation in the PD OFF-ON
contrast, consistent with the dopamine overdose hypothesis.
4.1. Cognitive functions mediated by striatum
The striatum mediates cognitive functions (Atallah et al., 2007;
MacDonald et al., 2014) in addition to its better-known role in motor
control. We independently assessed response-selection decisions and
stimulus-response learning, using behavioural measures and distinct
fMRI events. We aimed to disentangle neural substrates specifically
mediating these different cognitive processes. DS activation correlated
with stimulus-response decisions whereas VS signal arose preferentially
during delivery of feedback through which stimulus-response associa-
tions were learned. This entirely replicates our results in healthy, young
individuals (Hiebert et al., 2014). Beyond correlational evidence, how-
ever, in PD patients, we found clear double dissociations in DS- and
VS-mediated behaviour and preferential neural activity contrasting the
OFF and ON dopaminergic therapy states. PD patients demonstrated
enhanced stimulus-specific response-selection accuracy and DS activity
during Stimulus-Response Decision Events, compared to attenuated
stimulus-response association learning and VS activation during Feed-
back Events, on relative to off dopaminergic therapy. This pattern of
results provides strong support for the concept that DS mediates
response-selection decisions and not learning─ the latter being mediated
by VS rather.
Our results are completely at odds with the large literature attributing
feedback-based learning to DS (Yin and Knowlton, 2006; Balleine et al.,
2009; Hart et al., 2013). A potential explanation for the long-standing
association of DS with stimulus-response association learning, despite
increasing numbers of contradictory results (Reiss et al., 2005; Atallah
et al., 2007; Grahn et al., 2008; Ohira et al., 2010; Robertson et al., 2015),
relates to the common confounding of learning and decision-making
processes (McDonald and Hong, 2004; Jessup and O'Doherty, 2011;
Yang et al., 2017). In behavioural studies, learning is generally measured
by the accuracy of stimulus-specific response selections that are provided
as evidence that learning has occurred. Poor performance therefore could
be the result of failing either to learn stimulus-response associations or to
correctly select responses based on these learned associations. In fMRI
studies, a) enacting a response when presented with a stimulus, and b)
learning from feedback, are typically treated as a single event with all
significantly-activated brain regions ascribed a role in learning per se
(Poldrack et al., 1999; Jessup and O'Doherty, 2011; Dobryakova and
Tricomi, 2013). By separately assessing response-selection decisions and
learning, our approach aimed to resolve the discrepancy between studies
that involve DS in feedback-based learning (O'Doherty et al., 2004;
Boettiger and D'Esposito, 2005) versus those in PD patients (Swainson
et al., 2000; Vo et al., 2014), and participants with DS lesions (Exner
et al., 2002; Ell et al., 2006) that dispute the notion that DS mediates
stimulus-response learning.
Our findings integrate with a growing literature favouring a role for
DS in decision making rather than learning per se. In neuroimaging
studies, DS activity consistently remains significantly increased above
baseline after sequences (Reiss et al., 2005), categorization rules (Helie
et al., 2010; Seger et al., 2010), stimulus–reward (Daw and Doya, 2006;
Seger et al., 2010), and response–reward associations (Ohira et al., 2010)
are well learned. Additionally, DS frequently correlates with response
selections, particularly when an element of deliberation is required
(Hiebert et al., 2017), even in contexts devoid of new learning (Grahn et al.,
2008), such as in the Stroop task (Ali et al., 2010), and in making numeric
magnitude judgments (MacDonald et al., 2011). This activation profile is
inconsistent with a brain region mediating learning per se and is more in
line with one that underlies decisions.
Our results, in contrast suggest that VS mediates learning stimulus-
response associations. Replicating our previous findings (Hiebert et al.,
2014), VS signal occurred specifically during the Feedback Event and
correlated with efficiency of learning assessed with slope measure.
Further, learning efficiency and VS activation were reduced for PD pa-
tients on relative to off dopaminergic therapy, suggesting that VS, a
VTA-innervated structure, was overdosed by exogenous dopamine. This
result fits with the larger literature implicating VS in forms of implicit
learning (Tricomi et al., 2009; Sommer and Pollmann, 2016; Vo et al.,
2016; Pascucci et al., 2017; Vo et al., 2018), such as reward (Camara
et al., 2010), stimulus-stimulus (MacDonald et al., 2011), sequence
(Ghilardi et al., 2007), motor sequence (Feigin et al., 2003), and category
learning (Shohamy et al., 2006).
4.2. Interpretation of extra-striatal activations
In contrasts where DS activation emerged, cortical regions previously
implicated in decision making and categorization judgments were also
revealed. These included occipital regions of the fusiform gyrus that have
been implicated in decision making, specifically in motor planning and
execution (Tosoni et al., 2016), as well as the lateral occipital cortex
implicated in object recognition (Vernon et al., 2016). Object recognition
performed by the ventral visual stream, is a required step toward
enacting stimulus-specific response selections. The right middle frontal
gyrus has been shown to implement and reprogramme action plans
(Stock et al., 2016). Many of the brain regions that were significantly
activated along with DS during response-selection events are reciprocally
connected with the dorsal caudate nucleus, the body specifically, such as
the precentral, postcentral, inferior, and fusiform gyri (Robertson et al.,
2018; Tziortzi et al., 2014). These results highlight the fact that, whereas
the DS does not function in isolation, it plays a key, central role in per-
forming response-related decisions.
4.3. Effect of dopaminergic therapy on cognition in PD
The notion that abnormalities in dopamine across different brain
regions cause cognitive as well as motor symptoms in PD has long been
considered (Brown and Marsden, 1984; Gotham et al., 1988). Cognitive
functions mediated by SNc-innervated brain regions such as the DS are
expected to be improved by dopaminergic therapy, whereas the opposite
pattern is expected for VTA-supplied brain regions such as VS in PD. This
is due to different rates and degrees of degeneration of
dopamine-producing neurons in SNc and VTA in PD. This theoretical
framework successfully explains complex behavioural patterns in PD
(Cools, 2006; Vaillancourt et al., 2013). This framework is prevalent and
effectively accounts for behavioural patterns across a large number of PD
studies (Cools, 2006; Dirnberger and Jahanshahi, 2013; Vaillancourt
et al., 2013). Studies that fully support these concepts in a single
experiment are lacking, however. Here, we provide direct support for this
framework for understanding cognitive patterns in PD. We show for the
first time that dopaminergic therapy simultaneously a) improved
DS-mediated response selection and boosted DS signal and b) impaired
VS-mediated stimulus-response learning and attenuated VS activity.
Though a small number of previous investigations provide evidence of
improved DS function and increased DS activity (Aarts et al., 2014) or
impaired functions mediated by VTA-innervation brain regions and
corresponding reduced signal (Cools et al., 2007; Van Eimeren et al.,
2009; Kwak et al., 2012; Aarts et al., 2014), none have provided evidence
of these simultaneous and opposite effects within the same participants,
though a number of studies aimed to do so (Argyelan et al., 2008; Van
Eimeren et al., 2009; Shiner et al., 2012; Aarts et al., 2014).
5. Conclusions
Our findings dispute the prevalent notion that DS mediates stimulus-
response learning. We showed that DS mediates response selections
whereas VS underlies feedback-based learning in PD patients and healthy
age-matched controls. This study provides strong support for the view
that DS has been erroneously ascribed a role in feedback-based, stimulus-
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response learning due to methodology that confounds learning and
response-selection processes. Our findings integrate with a growing
literature favouring a role for DS in decision performance rather than
learning per se.
Values are presented as group means and standard error of the mean
(SEM) in braces. Screening cognitive and affective measures were
completed on medication unless otherwise stated. Dopaminergic therapy
was not administered to control (CTRL) participants at any time during
the experiment. Their data are presented here in the ON-OFF order
corresponding to their matched PD patient. Edu – Years of education;
Duration – Number of years since PD diagnosis; L-dopa (mg) - L-dopa
equivalent dose in mg; DA – number of PD patients on dopamine ago-
nists; UPDRS OFF – Unified Parkinson's disease rating scale motor score
off medication; UPDRS ON – Unified Parkinson's disease rating scale
motor score on medication; ANART – National Adult Reading Test IQ
Estimation; MOCA –Montreal Cognitive Assessment total score out of 30;
BDI-II OFF – Beck Depression Inventory II score measured when patients
with PD were off medication and for CTRL participants during the off
session of their corresponding PD patient; BDI-II ON – Beck Depression
Inventory II score measured when patients with PD were on medication
and for CTRL participants during the ON Session of their corresponding
PD patient; BAI OFF – Beck Anxiety Inventory score measured when
patients with PD were off medication and for CTRL participants during
the OFF Session of their corresponding PD patient; BAI ON – Beck Anx-
iety Inventory score measured when patients with PD were on medica-
tion and for CTRL participants during the ON Session of their
corresponding PD patient; Apathy OFF – Starkstein Apathy Scale score
measured when patients with PD were off medication and for CTRL
participants during the OFF Session of their corresponding PD patient;
Apathy ON – Starkstein Apathy Scale score measured when patients with
PD were on medication and for CTRL participants during the ON Session
of their corresponding PD patient.
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